NasdaqGS:LEGNBiotechs
Legend Biotech (LEGN) Reports LB2501 Progress, Is The Stock Still Cheap?
Legend Biotech (LEGN) has drawn fresh attention after reporting initial clinical proof of concept data for LB2501, an investigational in vivo CD19/CD20 dual targeting CAR T therapy in relapsed or refractory B cell non Hodgkin lymphoma.
See our latest analysis for Legend Biotech.
Legend Biotech's recent LB2501 update and follow on equity offering of about $226 million come after a sharp shift in sentiment, with the stock posting a 65.74% 3 month share price return but a 1 year total...